Hospitals and health startups face a paradox. They need massive, diverse datasets to innovate responsibly, yet regulations such as HIPAA and GDPR restrict how that data can be shared and analyzed. Synthetic data promises a solution by generating realistic, non-identifiable data that mimics patient populations without exposing personal records. But without clear governance, the same technology could replicate the inequities it aims to eliminate.
In the realm of artificial intelligence, many algorithms are trained in an evolutionary manner. These models improve through iterative feedback, much like natural selection rewards successful adaptations. Companies developing these systems often adopt a similar mindset: optimizing for growth, market share, and data acquisition. For both models and corporations, success depends on access to resources. In this context, those resources are data, whether drawn from users directly or simulated through advanced modeling. In hospitals, that means patient information—both clinical records protected under HIPAA and broader “alternative data” generated through patients’ interactions in the digital economy.
Alternative data refers to information that falls outside traditional medical charts and may not be safeguarded under existing privacy laws. In many cases, such data is critical for operations. As an example offered by Dr. Pramod Singh, in the unfortunate scenario of a mass casualty incident, population density metrics and hospital bed availability data can guide first responders and optimize emergency resource distribution. However, when the use of alternative data extends to financial profiling or patient screening, the ethical boundaries become blurred. Data intended to improve public health could just as easily be repurposed to limit access to care.
Synthetic data sits at the intersection of these opportunities and risks. Unlike anonymized datasets, synthetic data does not originate from identifiable individuals but is generated by statistical or machine learning models that simulate real-world patterns. This innovation enables researchers and practitioners to analyze realistic datasets without breaching patient confidentiality. Hospitals can test algorithms for sepsis detection or model the effects of bed shortages using synthetic patient records. In global collaborations, synthetic data allows institutions to share research insights without transferring identifiable information, maintaining compliance with privacy regulations like HIPAA in the United States or GDPR in the European Union.
Yet synthetic data introduces its own challenges. Studies such as Giuffrè and Shung (2023) emphasize that synthetic data cannot be assumed risk-free simply because it lacks direct identifiers. If the underlying models reproduce rare or unique characteristics, they can inadvertently enable re-identification when combined with external data sources. Moreover, biases embedded in the original datasets often carry over into their synthetic counterparts. If real-world data underrepresents certain populations, synthetic data will reinforce those disparities, potentially concealing bias beneath a veneer of statistical neutrality.
There is also the danger of “function creep,” where datasets or tools designed for one purpose migrate into ethically questionable uses. The same synthetic data that improves emergency response could, if paired with financial data, be used to predict a patient’s likelihood of payment or long-term profitability. This practice would conflict directly with the principles of beneficence and justice that underpin both medicine and responsible business practice. The ethical risk lies not only in the data itself but in the evolving incentive structures of the organizations that use it.
To ensure that synthetic data advances health equity rather than undermines it, stakeholders must look beyond technical accuracy and adopt a robust ethical framework. This framework should require transparency in how synthetic data is produced, explicit definition of its intended uses, and governance mechanisms that prevent repurposing for discriminatory or profit-driven goals. Regulatory agencies may also need to extend privacy protections to synthetic and alternative data, particularly as the distinction between “real” and “artificial” information grows increasingly porous.
The broader evolutionary metaphor remains instructive. Just as evolutionary algorithms optimize within their environments, corporations optimize for competitive advantage. The rapid expansion of synthetic data can be understood as part of this adaptive behavior as a strategy to innovate around regulatory limits. The challenge is ensuring that this evolution aligns with the ethical imperatives of medicine and public trust rather than diverging toward unregulated exploitation.
At Duke Health, researchers have used synthetic patient datasets to train predictive algorithms for sepsis detection. Because the data is simulated, these models can be tested and shared across departments without breaching HIPAA compliance. The result is faster development of life-saving tools and safer data collaboration. Yet the same methods could, in less regulated environments, be redirected to build predictive models of patient “value,” revealing how the same innovation can serve either public good or private gain depending on governance.
For healthcare organizations, startups, and data vendors, the lesson is clear: synthetic data is neither inherently safe nor inherently dangerous. Its value depends on how responsibly it is generated, applied, and overseen. The goal should not simply be compliance, but the cultivation of ethical resilience because the capacity to innovate while preserving fairness, privacy, and trust.
Define ethical guardrails early: Establish clear boundaries on acceptable use cases.
Audit for bias: Validate that generated data reflects the diversity of real patient populations.
Ensure transparency: Document methods of data generation and the purposes they serve.
Govern collaboratively: Include legal, clinical, and technical perspectives in oversight.
Evaluate vendors rigorously: Choose partners who demonstrate accountability and compliance.
Synthetic data represents one of the most promising tools for data-driven medicine, enabling innovation without directly compromising patient privacy. Yet it also reflects a broader evolutionary dynamic in which corporate and technological imperatives coevolve. The future of synthetic data will depend on our collective ability to channel that evolution toward ethical innovation rather than unchecked expansion. If guided by principles of fairness, transparency, and patient-centered care, synthetic data can serve as a catalyst for a smarter, more equitable healthcare system.